Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

Asan Medical Center

Status: Completed

Conditions: Metastatic Pancreatic Cancer; Pancreatic Cancer

Treatments: Drug: nab paclitaxel plus gemcitabine

Study type: Observational

Funder types: Other

Identifiers

NCT04133155

AX-NI-PANC-PI-13883

Details and patient eligibility

About

In this study, clinical data of patients who received 2nd-line Nab-paclitaxel plus Gemcitabine (nab-P+GEM) after progression on 1st-line FOLFIRINOX will be reviewed retrospectively.

Full description

FOLFIRINOX is one of standard 1 st-line regimens for patients with advanced PDAC. However, there is no globally established 2 nd-line regimen after the failure of FOLFIRINOX. Although gemcitabine-based regimens are recommended by multiple guidelines and widely used in daily practice, further analysis is needed to reveal the magnitude of clinical benefit with these regimens. Nab-paclitaxel plus Gemcitabine (Nab-P+Gem) is another standard 1 st-line regimen for PDAC, but there are limited data as 2 nd-line therapy in PDAC. Therefore, the investigators are conducting a multicenter retrospective analysis of 2 nd-line nab-P+Gem after progression on FOLFIRINOX in patients with advanced PDAC.

Enrollment: 103 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed pancreatic ductal adenocarcinoma
• Administration of 2nd-line nab-paclitaxel plus gemcitabine
• Progression on 1st-line FOLFIRINOX

Exclusion criteria

• Pathologic diagnosis other than pancreatic ductal adenocarcinoma
• Administration of nab-paclitaxel plus gemcitabine as 3rd or greater lines of therapy

Trial design

103 participants in 1 patient group

nab-P + GEM

Description:

Nab-paclitaxel plus gemcitabine

Treatment:

Drug: nab paclitaxel plus gemcitabine